Opiorphin in burning mouth syndrome patients: a case-control study
- First Online:
- 139 Downloads
Opiorphin is a pentapeptide isolated from human saliva that suppresses pain from chemically induced inflammation and acute physical pain. Burning mouth syndrome (BMS) is a chronic condition of a burning sensation in the mouth, where no underlying dental or medical cause can be identified. We aimed to measure the level of opiorphin in whole unstimulated (UWS) and stimulated (SWS) saliva of patients with BMS.
Materials and methods
Originally developed and validated LC-MS/MS method was used for opiorphin quantification. Samples were obtained from 29 BMS patients and 29 age- and sex-matched controls.
The average concentration of opiorphin in UWS and SWS in the BMS group was 8.13 ± 6.45 and 5.82 ± 3.59 ng/ml, respectively. Opiorphin in BMS patients’ UWS was significantly higher, compared to the control group (t = 2.5898; p = 0.0122). SWS opiorphin levels were higher, but not significantly, in BMS patients than in controls.
Our results indicate that higher quantities of salivary opiorphin in BMS may be a consequence of chronic pain, but we cannot exclude that they occur as a result of emotional and behavioral imbalances possibly associated with BMS. To our knowledge, this is the first original article measuring opiorphin in a pain disorder.
Opiorphin may be a measurable biomarker for chronic pain, which could help in objectifying otherwise exclusively a subjective experience. Increased opiorphin could serve as a universal objective indicator of painful conditions. Since opiorphin may also reflect emotional and socio-relational imbalances occurring with BMS, it could as well represent a biomarker for BMS. Knowledge on opiorphin’s involvement in pain pathways could contribute to developing new clinical diagnostic methods for BMS.
KeywordsOpiorphin Burning mouth syndrome Saliva Chromatography, Liquid Spectrometry, Mass
- 9.Rougeot C (2014) Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases. US patent US8642729 B2Google Scholar
- 12.Zakrzewska JM, Forssell H and Glenny AM (2005) Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev CD002779. doi:10.1002/14651858.CD002779
- 14.Grushka M, Ching V, Epstein V (2006) Burning mouth syndrome. Adv Othorinolaryngol 63:278–287Google Scholar
- 20.Sabalić M, Brkljačić L, Salarić I, Alajbeg I, Jerić I, Nemet I (2012) Salivary opiorphin as a potential marker of oral disease. Book of abstracts of the 11th Biennial Congress of the European Association of Oral Medicine. Oral Dis 18(1, SI):21Google Scholar
- 22.World Health Organization (2014) WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs. Available at: http://www.whocc.no/atc_ddd_publications/atc_ddd_index/
- 23.World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10). Geneva: WHO. Version for 2015. Available at: http://apps.who.int/classifications/icd10/browse/2015/en